Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation
Tóm tắt
Từ khóa
Tài liệu tham khảo
Cooper, 1984, Molecular cloning of a new transforming gene from a chemically transformed human cell line, Nature, 311, 29, 10.1038/311029a0
Naldini, 1991, Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET, Oncogene, 6, 501
Trusolino, 2010, MET signalling: principles and functions in development, organ regeneration and cancer, Nat Rev Mol Cell Biol, 11, 834, 10.1038/nrm3012
Schmidt, 1995, Scatter factor/hepatocyte growth factor is essential for liver development, Nature, 373, 699, 10.1038/373699a0
Uehara, 1995, Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor, Nature, 373, 702, 10.1038/373702a0
Goździk-Spychalska, 2014, c-MET inhibitors in the treatment of lung cancer, Curr Treat Options Oncol, 15, 670, 10.1007/s11864-014-0313-5
Scagliotti, 2013, The emerging role of MET/HGF inhibitors in oncology, Cancer Treat Rev, 39, 793, 10.1016/j.ctrv.2013.02.001
Awad, 2014, ALK inhibitors in non–small cell lung cancer: crizotinib and beyond, Clin Adv Hematol Oncol, 12, 429
Shaw, 2014, Crizotinib in ROS1-rearranged non–small-cell lung cancer, N Engl J Med, 371, 1963, 10.1056/NEJMoa1406766
Kwak, 2010, Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer, N Engl J Med, 363, 1693, 10.1056/NEJMoa1006448
Camidge, 2014, Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non–small cell lung cancer (NSCLC), J Clin Oncol, 32, 10.1200/jco.2014.32.15_suppl.8001
Kong-Beltran, 2006, Somatic mutations lead to an oncogenic deletion of met in lung cancer, Cancer Res, 66, 283, 10.1158/0008-5472.CAN-05-2749
Onozato, 2009, Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers, J Thorac Oncol, 4, 5, 10.1097/JTO.0b013e3181913e0e